Answers are grounded in this paper and cite their sources.
Bone repair requires a coordinated transition from inflammation to regeneration. Regulatory T cells (Tregs) participate in this transition through immune suppression, interactions with macrophages, and signals that support skeletal progenitors. Their extracellular vesicles (Treg-EVs) provide a complementary means of transferring selected regulatory activities without administering living cells. Recent studies have connected these biological mechanisms to local therapeutic platforms, including Treg-loaded fibrin hydrogels, materials that recruit endogenous Tregs, and injectable systems delivering Treg-EVs with progenitor-recruiting factors. This Mini Review examines these approaches while distinguishing fracture and bone-defect repair from ectopic osteogenesis and protection against inflammatory bone loss. We discuss how IL-10, amphiregulin, progranulin, and vesicular purinergic signaling inform delivery design, and why cellular mechanisms cannot automatically be assigned to EV preparations. Particular attention is given to therapeutic timing, material–immune interactions, cell identity, vesicle heterogeneity and potency, and causal evaluation.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: